Compound ID | 253
Synonym(s): GSK2140944
Class: DNA synthesis inhibitor
| Agent Type: | Synthetic; Small molecule; Direct acting; |
| Spectrum of activity: | Gram-positive & Gram-negative |
| Mechanism of action: | DNA synthesis inhibitor. Bacterial topoisomerase inhibitor |
| Target Pathogen: | Active against methicillin-resistant Staphylococcus aureus and pathogens causing respiratory tract infections, acute bacterial skin and skin structure infections (ABSSI), and uncomplicated urogenital gonorrhoea |
| Institute where first reported: | GlaxoSmithKline, UK |
| Year first mentioned: | 2011 |
| Highest development stage: | Approved by FDA in 2025 |
| Development status: | Approved |
| External links: | |
| PubChem link: | https://pubchem.ncbi.nlm.nih.gov/compound/25101874 |
| Guide to Pharmacology: | gepotidacin |
| Citations: |
|
| Patent: | WO2021219637A1 |